← All trials
NCT04656301
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2021
- Primary completion
- Jul 31, 2022
- Completion date
- Aug 31, 2022
- First posted
- Dec 7, 2020
- Last posted
- Dec 7, 2020
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Columbia UniversityLead sponsor
- COMPASS PathwaysCollaborator
- Columbia UniversityReponsible party - principal investigator
- Columbia UniversityOverall official - principal investigator
- Columbia UniversitySponsor investigator
- University of California, Los AngelesCollaborator
- Columbia UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.